Elevation Oncology Stock News

Vanguard Group Inc. acquired a new position in shares of Elevation Oncology, Inc. (NASDAQ:ELEV) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 60,000 shares of the companys stock, valued at approximately $814,000. Vanguard Group Inc. owned approximately 0.26% of Elevation Oncology as of []

NeoGenomics with ticker code (NEO) have now 10 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 60 and 45 with a mean TP of 51.7. Given that the stocks previous close was at 37.28 this would indicate that there is a potential upside of 38.7%. The day 50 moving average is 44.06 and the 200 moving average now moves to 45.69. The market capitalisation for the company is $4,633m. Visit the company website at: /> [stock_market_widget type="chart" symbol="NEO" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] NeoGenomics operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.

NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomic

Related Stocks: ELEV , APLS ,

Related Stocks: SPY , EFA , ELEV , SBBP , ISEE , AJAX , ONCS , ISOS.U , SRNGU ,

Elevation Oncology (NASDAQ:ELEV) announced its earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.15), MarketWatch Earnings reports. Shares of NASDAQ:ELEV opened at $7.69 on Friday. Elevation Oncology has a 52 week low of $7.38 and a 52 week high of $16.22. The []

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomic

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

NEW YORK, June 24, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomic